Access the full text.
Sign up today, get DeepDyve free for 14 days.
Zhifei Sun, M. Adam, Jina Kim, D. Nussbaum, E. Benrashid, C. Mantyh, J. Migaly (2016)
Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon CancerDiseases of the Colon & Rectum, 59
J. Biagi, M. Raphael, W. Mackillop, W. Kong, W. King, C. Booth (2011)
Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis.JAMA, 305 22
J. Panchal, D. Lairson, W. Chan, Xianglin Du (2016)
Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon CancerAmerican Journal of Therapeutics, 23
L. Sobin, I. Fleming (1997)
TNM classification of malignant tumors, fifth edition (1997)Cancer, 80
F. Greene (2007)
Current TNM staging of colorectal cancer.The Lancet. Oncology, 8 7
I. Nagtegaal, N. Knijn, N. Hugen, H. Marshall, K. Sugihara, T. Tot, H. Ueno, P. Quirke (2017)
Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging-A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 10
M. Weiser (2018)
AJCC 8th Edition: Colorectal CancerAnnals of Surgical Oncology, 25
G. Malietzis, Aamer Mughal, A. Currie, N. Anyamene, R. Kennedy, T. Athanasiou, J. Jenkins (2015)
Factors Implicated for Delay of Adjuvant Chemotherapy in Colorectal Cancer: A Meta-analysis of Observational StudiesAnnals of Surgical Oncology, 22
N. Goldstein, J. Turner (2000)
Pericolonic tumor deposits in patients with T3N+M0 colon adenocarcinomasCancer, 88
Osama Sahaf, E. Myers, M. Jawad, T. Browne, D. Winter, H. Redmond (2011)
The Prognostic Significance of Extramural Deposits and Extracapsular Lymph Node Invasion in Colon CancerDiseases of the Colon & Rectum, 54
A. Becerra, Christian Probst, M. Tejani, C. Aquina, Maynor González, Bradley Hensley, K. Noyes, J. Monson, F. Fleming (2015)
Opportunity lost: Adjuvant chemotherapy in patients with stage III colon cancer remains underused.Surgery, 158 3
G. Yothers, M. O’connell, C. Allegra, J. Kuebler, L. Colangelo, N. Petrelli, N. Wolmark (2011)
Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 28
C. Twelves, A. Wong, M. Nowacki, M. Abt, H. Burris, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulias, F. Husseini, D. Jodrell, P. Koralewski, H. Kröning, J. Maroun, N. Marschner, J. Mckendrick, M. Pawlicki, R. Rosso, J. Schüller, J. Seitz, B. Štabuc, J. Tujakowski, G. Hazel, J. Zaluski, W. Scheithauer (2005)
Capecitabine as adjuvant treatment for stage III colon cancer.The New England journal of medicine, 352 26
A. Bos, F. Erning, Y. Gestel, G. Creemers, C. Punt, M. Oijen, V. Lemmens (2015)
Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer.European journal of cancer, 51 17
S. Ong, J. Watters, E. Grunfeld, K. O'rourke (2005)
Predictors of referral for adjuvant therapy for colorectal cancer.Canadian journal of surgery. Journal canadien de chirurgie, 48 3
M. Jin, R. Roth, J. Rock, M. Washington, A. Lehman, W. Frankel (2015)
The Impact of Tumor Deposits on Colonic Adenocarcinoma AJCC TNM Staging and OutcomeThe American Journal of Surgical Pathology, 39
R. Deyo, D. Cherkin, D. Cherkin, M. Ciol (1992)
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.Journal of clinical epidemiology, 45 6
K. Bilimoria, A. Stewart, D. Winchester, C. Ko (2008)
The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 15
H. Ueno, H. Mochizuki, K. Shirouzu, T. Kusumi, Kazutaka Yamada, M. Ikegami, H. Kawachi, S. Kameoka, Y. Ohkura, T. Masaki, R. Kushima, Keiichi Takahashi, Y. Ajioka, K. Hase, A. Ochiai, R. Wada, K. Iwaya, Takahiro Nakamura, K. Sugihara (2011)
Actual status of distribution and prognostic impact of extramural discontinuous cancer spread in colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 18
G. Guetz, P. Nicolas, G. Perret, J. Morère, B. Uzzan (2010)
Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis.European journal of cancer, 46 6
K. Nagayoshi, T. Ueki, Y. Nishioka, T. Manabe, Y. Mizuuchi, M. Hirahashi, Y. Oda, Masao Tanaka (2014)
Tumor Deposit Is a Poor Prognostic Indicator for Patients Who Have Stage II and III Colorectal Cancer With Fewer Than 4 Lymph Node Metastases but not for Those With 4 or MoreDiseases of the Colon & Rectum, 57
H. Sanoff, W. Carpenter, T. Stürmer, R. Goldberg, Christopher Martin, J. Fine, N. McCleary, J. Meyerhardt, J. Niland, K. Kahn, M. Schymura, D. Schrag (2012)
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
J. Kuebler, H. Wieand, M. O’connell, Roy Smith, L. Colangelo, G. Yothers, N. Petrelli, M. Findlay, T. Seay, J. Atkins, J. Zapas, J. Goodwin, L. Fehrenbacher, R. Ramanathan, B. Conley, P. Flynn, G. Soori, L. Colman, E. Levine, K. Lanier, N. Wolmark (2007)
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 16
Haejin In, K. Bilimoria, Andrew Stewart, Kristen Wroblewski, Mitchell Posner, M. Talamonti, David Winchester (2014)
Cancer Recurrence: An Important but Missing Variable in National Cancer RegistriesAnnals of Surgical Oncology, 21
S. Edge, C. Compton (2010)
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 17
A. Benson, A. Venook, T. Bekaii-Saab, E. Chan, Yi-Jen Chen, H. Cooper, P. Engstrom, P. Enzinger, M. Fenton, C. Fuchs, J. Grem, S. Hunt, A. Kamel, L. Leong, E. Lin, W. Messersmith, M. Mulcahy, James Murphy, Steven Nurkin, E. Rohren, D. Ryan, L. Saltz, Sunil Sharma, D. Shibata, J. Skibber, C. Sofocleous, E. Stoffel, E. Stotsky-Himelfarb, C. Willett, K. Gregory, Deborah Freedman-Cass (2014)
Colon cancer, version 3.2014.Journal of the National Comprehensive Cancer Network : JNCCN, 12 7
L. Jin, D. Sanford, M. Squires, L. Moses, Yan Yan, G. Poultsides, K. Votanopoulos, S. Weber, M. Bloomston, T. Pawlik, W. Hawkins, D. Linehan, C. Schmidt, David Worhunsky, A. Acher, K. Cardona, C. Cho, D. Kooby, E. Levine, E. Winslow, Neil Saunders, G. Spolverato, G. Colditz, S. Maithel, R. Fields (2016)
Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer CollaborativeAnnals of Surgical Oncology, 23
T. Abrams, Rick Brightly, Jianbin Mao, G. Kirkner, J. Meyerhardt, D. Schrag, C. Fuchs (2011)
Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 24
John Harrison, P. Dean, F. El-Zeky, R. Zwaag (1995)
Impact of the Crohn's-like lymphoid reaction on staging of right-sided colon cancer: results of multivariate analysis.Human pathology, 26 1
M. Morris, Cameron Platell, Lin Fritschi, Barry Iacopetta (2007)
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patientsBritish Journal of Cancer, 96
E. Belt, M. Stijn, H. Bril, E. Klerk, G. Meijer, S. Meijer, H. Stockmann (2010)
Lymph Node Negative Colorectal Cancers with Isolated Tumor Deposits Should Be Classified and Treated As Stage III
T. André, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, I. Tabah-Fisch, A. Gramont (2004)
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.The New England journal of medicine, 350 23
BACKGROUND: The prognosis of tumor deposits in stage III colon adenocarcinoma is poorly described. OBJECTIVE: The purpose of this study was to determine the impact of tumor deposits on oncologic outcomes in patients with stage III colon cancer. DESIGN: This was a multicenter retrospective cohort study. SETTINGS: The 2010 to 2014 National Cancer Database was queried for patients with resected stage III colon adenocarcinoma on final pathology. PATIENTS: Patients were divided into 3 groups: lymph nodes+tumor deposits–, lymph nodes+tumor deposits+, and lymph nodes–tumor deposits+. MAIN OUTCOME MEASURES: The main outcome was 5-year overall survival. RESULTS: Of 74,577 patients, there were 55,800 patients with lymph nodes+tumor deposits–, 13,740 patients with lymph nodes+tumor deposits+, and 5037 patients with lymph nodes–tumor deposits+. The groups had similar patient and facility characteristics, but patients with lymph nodes+tumor deposits+ had more advanced tumor characteristics. Patients with lymph nodes–tumor deposits+ were less likely to receive adjuvant systemic therapy (52% vs 74% lymph nodes+tumor deposits– and 75% lymph nodes+tumor deposits+, p < 0.001) and had a longer delay to initiation of adjuvant treatment (>8 weeks; 43% vs 33% lymph nodes+tumor deposits– and 33% lymph nodes+tumor deposits+, p < 0.001). Patients with lymph nodes+tumor deposits+ had the lowest 5-year overall survival (46.0% vs 63.4% lymph nodes+tumor deposits– vs 61.9% lymph nodes–tumor deposits+, p < 0.001). On multivariate analysis, patients with lymph nodes–tumor deposits+ had similar 5-year overall survival compared with patients with lymph nodes+tumor deposits– with ≤3 positive lymph nodes (HR, 0.93; 95% CI, 0.87–1.01). Patients with lymph nodes+tumor deposits+ had worse prognosis regardless of the number of involved lymph nodes (≤3 +lymph nodes: HR, 1.37; 95% CI, 1.28–1.47 and ≥4 +lymph nodes: HR, 1.30; 95% CI, 1.22–1.38). Of those not receiving adjuvant treatment, patients with lymph nodes–tumor deposits+ were younger and had more adverse tumor features than lymph node+ disease. Lymph nodes–tumor deposits+ was independently associated with less delivery of adjuvant systemic therapy (OR, 0.81; 95% CI, 0.80–0.82). LIMITATIONS: This study was limited by its retrospective analysis of a prospective database. CONCLUSIONS: The prognosis of patients with N1c disease is similar to nodal involvement without tumor deposits, yet these patients were less likely to receive adjuvant systemic therapy. Improvement in the delivery of appropriate care in these patients may increase survival and should be a target of future quality initiatives. See Video Abstract at http://links.lww.com/DCR/A666.
Diseases of the Colon & Rectum – Wolters Kluwer Health
Published: Sep 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.